Given that PD-L1 expression further declined in the recurrent tumor (CPS = 1), the loss of antigen presentation may have been due to downregulated MHC class I expression, reducing tumor cell visibility to cytotoxic T cells, despite continued immunotherapy exposure [59]. This evidence concerns the gene CD274 and neoplasm.